HRCT revealed parenchymal lung abnormalities in ACPA-positive RA patients and further molecular studies on bronchoalveolar lavage (BAL) fluid highlighted the increased levels of ACPAs in lung compartments compared to the sera of ACPA-positive RA patients, suggesting a lung-specific production of ACPAs. Here, PRTN3 is linked to rheumatoid arthritis.